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Abstract
Introduction:
Stress-induced hyperglycemia increases morbidity and mortality. Tight control can reduce mortality but has 
proven difficult to achieve. The SPRINT (Specialized Relative Insulin and Nutrition Tables) protocol is the only 
protocol that reduced both mortality and hypoglycemia by modulating both insulin and nutrition, but it has not 
been tested in independent hospitals.
Methods:
SPRINT was used for 12 adult intensive care unit patients (949 h) at Kálmán Pándy Hospital (Gyula, Hungary) 
as a clinical practice assessment. Insulin recommendations (0–6 U/h) were administered via constant infusion 
rather than bolus delivery. Nutrition was administered per local standard protocol, weaning parenteral to enteral 
nutrition, but was modulated per SPRINT recommendations. Measurement was every 1 to 2 h, per protocol. 
Glycemic performance is assessed by percentage of blood glucose (BG) measurements in glycemic bands for the 
cohort and per patient. Safety from hypoglycemia is assessed by numbers of patients with BG < 2.2 (severe) 
and %BG < 3.0 and < 4.0 mmol/liter (moderate and light). Clinical effort is assessed by measurements per day. 
Results are median (interquartile range).
Results:
There were 742 measurements over 1088 h of control (16.4 measurements/day), which is similar to clinical 
SPRINT results (16.2/day). Per-patient hours of control were 65 (50–95) h. Initial per-patient BG was 10.5 
(7.9–11.2) mmol/liter. All patients (100%) reached 6.1 mmol/liter. Cohort BG was 6.3 (5.5–7.5) mmol/liter, 
with 42.2%, 65.1% and 77.6% of BG in the 4.0–6.1, 4.0–7.0, and 4.0–8.0 mmol/liter bands. Per-patient, median 
percentage time in these bands was 40.2 (26.7–51.5)%, 62.5 (46.0–75.7)%, and 74.7 (61.6.8–87.8)%, respectively. 
No patients had BG < 2.2 mmol/liter, and the %BG < 4.0 mmol/liter was 1.9%. These results were achieved using 
3.0 (3.0–5.0) U/h of insulin with 7.4 (4.4–10.2) g/h of dextrose administration (all sources) for the cohort. Per-patient 
median insulin administration was 3.0 (3.0–3.0) U/h and 7.1 (3.4–9.6) g/h dextrose. Higher carbohydrate 
nutrition formulas than were used in SPRINT are offset by slightly higher insulin administration in this study.
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Introduction
Stress-induced hyperglycemia and excessive glycemic 
variability in the critically ill increase morbidity and mor-
tality.1–5 Accurate glycemic control can reduce mortality6–9 
and organ failure,10,11 as well as other morbidities.7 
However, these results have proven difficult to achieve 
consistently.12–14 Increased hypoglycemia, which carries 
its own risk,15–17 has also been prevalent, where only the 
SPRINT (Specialized Relative Insulin and Nutrition Tables) 
study9 reduced both mortality and hypoglycemia.
SPRINT maintains blood glucose (BG) levels in a goal 
target band of 4.0–6.1 mmol/liter, and 80% of BG was in 
a 4.0–7.0mmol/liter band, minimizing hyperglycemic 
risk. SPRINT, as designed, has three unique features18,19: 
(1) use of bolus insulin delivery for safety from infusions 
being left on if measurements are missed, (2) direct control 
of (low-carbohydrate) nutrition as part of controlling 
glycemia, and (3) a 1 or 2 h measurement and intervention 
cycle. In contrast, the majority of other published 
protocols primarily use insulin infusions to maintain 
glycemia. Bolus insulin administration avoids high 
insulin infusion rates being left running if clinical staff 
become occupied, reducing the risk of hypoglycemia.18 This 
issue is especially evident in situations with high insulin 
infusion rates coupled with infrequent measurement 
intervals, and has led to the high rates of hypoglycemia 
seen in many studies.20 In addition, almost all studies 
leave nutrition to local clinical standards or choice12–14,21,22 
and do not consider it in controlling glycemia, despite 
its direct relationship to BG outcome, with a resultant 
increase in glycemic variability and hypoglycemia23 
and thus likely affected outcomes.4,5,15–17,24,25 Finally, 4 h 
measurement intervals are common to many protocols, 
which also increases glycemic variability and reduces 
the quality of control.19
Computerized protocols can also achieve superior 
results.26–29 However, their complexity can make them 
difficult to implement. SPRINT was specifically designed 
to provide an easy-to-use equivalent and achieve equal 
overall glycemic control to computerized protocols.19,30–32
However, SPRINT has not been formally evaluated outside 
the Christchurch intensive care unit (ICU) for which it 
was developed. Some multicenter studies have reported 
significant variation in the quality or outcome of a 
given protocol across units, showing potentially poor 
robustness of protocols across different cohorts and 
clinical practice cultures.13,14 This research presents the 
data from a pilot trial of the SPRINT protocol in an 
independent ICU with a different clinical practice culture. 
The goal is to determine if SPRINT can achieve the same 
level of performance and safety in this different unit, 
despite differences in how the protocol is applied in 
terms of insulin administration and the type of nutrition 
formulas used. These are critical differences that vary 
significantly across units but reflect the types of changes 
any protocol might undergo if attempted in a different unit. 
Thus the goal is to test the robustness of the approach 
(modulating insulin and nutrition) and dosing (the 
specific recommendations) for safety and efficacy.
Methods
SPRINT Protocol
SPRINT uses current and previous BG measurements 
in conjunction with the previous nutrition and insulin 
rates to determine the hourly enteral (EN) nutrition rate 
and insulin bolus to minimize hyperglycemia and 
hypoglycemia. The protocol consists of two wheels 
dedicated to nutrition and insulin administration, as 
Abstract cont.
Conclusions:
The glycemic performance shows that using the SPRINT protocol to guide insulin infusions and nutrition 
administration provided very good glycemic control in initial pilot testing, with no severe hypoglycemia. 
The overall design of the protocol was able to be generalized with good compliance and outcomes across 
geographically distinct clinical units, patients, and clinical practice.
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shown in Figures 1 and 2, where the English versions 
are shown for clarity, but Hungarian translated versions 
were used in practice. It aims to keep the BG between 
4.0 and 6.1 mmol/liter with minimal variability using 
measurements taken every 1 to 2 h. All blood samples 
are taken from the arterial cannula to maximize patient 
comfort. If no arterial cannula is present, blood is taken 
via pin stick from the toes or fingers, but only every 
2 h to minimize discomfort. Nutrition is modulated 
between 30% and 100% in 10% increments of a patient-
specific goal feed based on the American College of 
Chest Physicians (ACCP) guidelines of 25 kcal/kg/day.33 
Intravenous insulin is recommended from 0–6 U/h in 
1 U increments. Initial results in Christchurch in the 
before–after study of 800 patients reported very tight 
control and minimal severe hypoglycemia <3% by 
patient (8 of 371 patients).9
Figure 3 shows the decision tree for going to measure-
ments every 2 h when the patient is glycemically stable. 
Glycemic stability is defined as 3 h in the 4.0 to 
6.1 mmol/liter band with 3 U or less insulin per hour 
and 60% or more of total feed rate. Such a patient is thus 
not significantly insulin resistant and is in the target 
band, making sudden changes potentially less likely and 
allowing less frequent measurement. SPRINT is stopped 
when the patient is normoglycemic and adequately 
self-regulating. This state is characterized as stable within 
the 4–6.1mmol/liter band for the past 6 h, with an 80% 
rate of goal feed or higher and insulin of 2 U/h or less. 
The stopping decision tree is shown in Figure 4. Note that 
both Figures 3 and 4 were translated into Hungarian by 
local speakers for clinical use.
Pilot Study
SPRINT was implemented as a clinical practice assessment 
at Kálmán Pándy Hospital (Gyula, Hungary) but did not 
displace another formal method. Patients started on the 
protocol if they had BG > 8 mmol/liter or by clinical 
decision. Per protocol, BG measurements were made 
Figure 1. The SPRINT feed wheel with dial with instructions in English, with dial removed to show all values. A translated version with 
Hungarian instructions (not shown) was used clinically.
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Figure 2. The SPRINT insulin wheel with dial with instructions in English, with dial removed to show all values. A translated version with 
Hungarian instructions (not shown) was used clinically.
using blood sampled from the arterial line and bedside 
glucometers (Dcont Personal and Dcont Optimum by 77 
Elektronika Kft, Hungary). Patients were stopped per the 
conditions in Figure 4 or on ICU discharge. There are 
no specific exclusion criteria.
Patients were fed a mixture of EN and parenteral (PN) 
nutrition, per local clinical practice. The combined 
carbohydrate content was calculated and used to obtain 
the goal rate. In the protocol, this goal or maximum rate 
was adjusted for both EN and PN to the recommended 
levels. It is very important to note that, in this study, 
insulin was given by infusion, rather than bolus, to 
match current clinical practice in this unit. SPRINT also 
allowed clinicians to prescribe, as needed, an added 
background rate of 0.5–2.0 U/h, which was not done in 
this case.
There are thus three areas where this implementation of 
SPRINT was adapted to meet local standards different 
from those in Christchurch.9 First, insulin was given as 
constant infusions of the same unit/hour rate, rather 
than bolus delivery. Second, the Christchurch unit9 used 
very little PN nutrition, favoring a strictly EN route. 
However, the Gyula unit prefers weaning PN to EN 
mixture. This mixture was thus adjusted by moving 
both EN and PN values to ensure the percentage from 
carbohydrates remained constant. The percentile feed 
stickers that convert percentage goal feed to pump rates 
were modified to show the required rate for both EN and 
PN so that the use of SPRINT by nurses was effectively 
the same. Third, while the total calories are similar, a 
higher overall carbohydrate concentration of ~50% 
was preferred in Gyula versus the lower carbohydrate 
formulas (~35–38% calories from carbohydrate) used in 
Christchurch.9 These differences led us to hypothesize 
that this implementation of SPRINT would yield 
slightly higher overall BG concentrations based on high 
carbohydrate concentration, all else equal. Thus, while 
the protocol itself was little changed, these differences, 
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Figure 3. Decision tree used by nurses to determine when to measure BG every 2 h.
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Figure 4. Decision tree used by nurses to determine when to stop SPRINT protocol.
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due to local clinical practice culture, would test how well 
SPRINT generalizes in terms of safety and efficacy.
This pilot study included 12 individuals, described in 
Table 1, who provide a general cross section of this ICU 
population for this pilot trial. The median [interquartile 
range (IQR)] age was 59 (37–68) years, 66% (8 of 12) 
were male, and 25% (3 of 12) had previously diagnosed 
diabetes. Note that illness severity scores are not typically 
used in this hospital. According to the local ethical codes, 
this pilot study was considered as a clinical data audit, 
and the only ethics committee requirement was the 
depersonalization of the data collected.
Results
Table 2 summarizes the results and indicates that SPRINT 
achieved safe and tight glucose control while still 
maintaining relatively high levels of feed and moderate 
levels of insulin. Individual patient summaries are 
presented in Table 3. The median (IQR) per-patient hours 
of control was 65.5 (49.5–94.5) h, totaling 1088 total hours 
of control over the cohort.
With respect to performance, overall median (IQR) 
cohort BG was 6.3 (5.5–7.5) mmol/liter, achieved giving 
Table 1.
Pilot Study Patient Cohort
Patient 
number Primary diagnoses Age Sex
Diagnosed
diabetes
ICU 
mortality 
1 Pancreatitis 90 F N
2 Antifreeze intoxication 28 M N
3 Pancreatitis 38 F N
4 Ketoacidosis 21 M Y N
5 Coma 57 M Y
6
Pneumonia, 
respiratory 
insufficiency, 
ketoacidosis
44 F Y N
7 Pneumonia 72 M N
8 Pancreatitis 61 F N
9 Coronary artery bypass graft, sepsis 61 M Y N
10 Coma, respiratory failure, head injury 67 M Y
11 Pancreatitis 33 M N
12 Ketoacidosis 79 M N
Median (IQR) or %male or 
#diabetes
59 
(37–
68)
66% 3 2 of 12
7.1 (3.4–9.6) g/h of carbohydrate nutrition and 3.0 
(3.0–5.0) U/h of insulin. Time in the 4.0–6.1, 4.0–7.0, and 
4.0–8.0 mmol/liter bands was 42.2%, 65.1%, and 77.6%, 
respectively. Time in the 4.4–7.0 and 4.4–8.0 mmol/liter 
bands was 63.3% and 80.9%, respectively. Thus only 
1.9% of measurements were below 4.0 mmol/liter and 
14.3% were above 8.0 mmol/liter. Figure 5 summarizes 
the per-patient glycemic control results, showing the 
range of BG cumulative distribution functions for all 
Table 2.
Summary of Pilot Cohort Results for SPRINT in 
Gyula, Hungary, Compared with SPRINT Study 
Results in Christchurch9a
Gyula Pilot Christchurch9
Total patients 12 371
Total trial hours 1088 44,542
Total measurements 742 27,601
Per-patient BG control parameters
Hours of control 65.5 (49.5–94.5) 53.0 (19.0–147.0)
Initial BG 10.5 (7.9–11.2) 8.9 (7.3–10.8)
Minimum BG (mmol/liter) 3.60 (3.30–4.00) 3.70 (3.20–4.30)
%BG in 4.0–6.1 mmol/liter 40.2 (26.7–51.5) 56.3 (41.5–70.0)
%BG in 4.0–7.0 mmol/liter 62.5 (46.0–75.7) 77.2 (63.6–86.8)
%BG in 4.0–7.75 mmol/liter 74.7 (61.6–87.8) 84.9 (72.4–93.3)
%BG in 4.4–7.0 mmol/liter 68.9 (44.1–79.7) 73.7 (59.8–84.6)
%BG in 4.4–8.0 mmol/liter 82.9 (67.8–89.0) 83.3 (69.2–91.5)
Number of patients BG < 2.2 
mmol/liter 0 8
Insulin administration (U/h) 3.0 (2.2–5.0) 3.0 (2.0–3.0)
Nutrition: carbohydrate (g/h) 7.4 (4.4–9.7) 3.8 (1.6–5.5)
Cohort BG distribution
BG median 6.3 (5.5–7.5) 5.7 (5.0–6.4)
%BG in 4.0–6.1 mmol/liter 42.2% 63.6%
%BG in 4.0–7.0 mmol/liter 65.1% 82.8%
%BG in 4.0–7.75 mmol/liter 77.6% 89.6%
%BG in 4.4–7.0 mmol/liter 63.3% 78.1%
%BG in 4.4–8.0 mmol/liter 80.9% 86.3%
%BG in 8.0–10.0 mmol/liter 12.5% 4.3%
%BG > 10.0 mmol/liter 2.8% 1.9%
%BG < 4.4 mmol/liter 3.7% 7.4%
%BG < 4.0 mmol/liter 1.9% 2.8%
%BG < 3.0 mmol/liter 0.3% 0.2%
a Results are median (IQR) as appropriate. Note that there are 
two sets of glycemic control bands reported to enable better 
comparison to Christchurch9 as well as other ranges in the 
literature.
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Table 3.
Summary of Per-Patient Resultsa
Patient number 1 2 3 4 5 6 7 8 9 10 11 12
Trial length (h) 53 72 87 46 53 91 39 59 75 40 334 128
Number of 
measurements 32 64 47 39 37 52 24 46 62 25 223 88
Initial BG  
(mmol/liter) 11.5 4.5 8.6 15.8 9.8 10.7 16.9 5.7 10.3 10.8 7.3 10.8
BG median  
(IQR; mmol/liter)
5.8
(5.2–6.6)
5.8
(5.0–6.4)
7.5
(6.8–8.3)
7.1
(5.9–8.0)
6.9
(5.7–7.8)
5.8
(5.3–6.8)
7.0
(6.0–8.7)
5.9
(5.4–6.7)
7.8
(7.1–8.8)
6.2
(5.6–6.7)
6.2
(5.5–7.2)
6.0
(5.2–7.2)
Minimum BG 3.6 3.6 3.6 2.9 3.9 3.3 4.1 3.8 4.2 4.6 2.5 3.3
%BG < 4.0 1.9 2.7 0.0 4.3 1.9 1.9 0.0 3.3 0.0 0.0 2.7 1.6
%BG in 4.0–6.1 
mmol/liter 59.3 63.0 8.0 31.9 27.8 57.3 27.5 55.0 13.2 46.3 44.8 51.9
%BG in 4.0–7.0 
mmol/liter 85.2 87.7 37.5 42.6 51.9 81.6 52.5 75.0 23.7 82.9 68.7 72.1
%BG in 4.0–7.75 
mmol/liter 92.6 93.2 58.0 68.1 72.2 89.3 65.0 88.3 43.4 90.2 81.2 78.3
%BG in 4.4–7.0 
mmol/liter 81.5 80.8 37.5 38.3 51.9 78.6 50.0 73.3 22.4 82.9 68.1 69.8
%BG in 4.4–8.0 
mmol/liter 88.9 89.0 65.9 68.1 79.6 86.4 67.5 90.0 59.2 92.7 86.3 79.1
%BG in 8.0–10.0 
mmol/liter 0.0 1.4 35.2 21.3 18.5 4.9 25.0 5.0 39.5 4.9 10.4 15.5
%BG > 10.0 
mmol/liter 5.6 0.0 0.0 6.4 0.0 3.9 7.5 0.0 3.9 2.4 2.7 3.9
Carbohydrate 
nutrition median 
(IQR; g/h)
9.1
(8.1–11.5)
10.8
(9.3–12.0)
15.6 
(15.6–15.6)
2.8
(0.0–4.2)
3.1
(2.7–3.5)
5.6
(5.2–7.8)
4.4
(4.4–6.0)
9.7
(7.4–9.7)
3.0
(3.0–4.6)
7.1
(4.5–8.1)
7.4
(4.4–10.2)
4.7
(2.0–5.7)
Insulin median 
(IQR; U/h)
3.0
(3.0–4.0)
3.0
(2.0–3.1)
5.0
(4.0–5.0)
3.0
(0.0–4.0)
3.0
(3.0–5.0)
3.0
(2.2–3.0)
3.0
(0.5–4.8)
3.0
(3.0–3.0)
5.0
(4.0–5.0)
2.0
(2.0–3.0)
3.0
(3.0–5.0)
2.0
(2.0–3.0)
a Note that there are two sets of glycemic control bands reported to enable better comparison to Christchurch9 as well as other ranges in 
the literature.
Figure 5. Cumulative distribution functions for BG results for all patients. 
The heavy dashed line is the median patient and the shaded areas 
show the IQR and 90% confidence interval. Overall results were tight 
across patients.
patients and indicating the 5th, 25th, median, 75th, and 
95th percentile patient results, which are also reflected in 
Tables 2 and 3. Note that the higher carbohydrate nutrition 
used in this unit is reflected, in part, in the approximately 
0.5 mmol/liter higher BG achieved overall in Table 2 and 
is seen in each patient in Table 3 as well. Equally, the 
reduction of 2.8% to 1.9% of BG < 4.0 mmol/liter in 
Table 2 for this pilot study also reflects these slightly 
higher resulting BG levels. Per-patient results were 
relatively tight across the cohort as summarized in Table 3 
and Figure 5, showing SPRINT was able to manage 
interpatient variability.
With regard to safety, no instances of severe hypo-
glycemia (defined as BG < 2.2 mmol/liter) were recorded. 
There was 1.9% of measured BG < 4.0 mmol/liter and 
0.3% BG < 3.0 mmol/liter. These results are better than 
those reported for the original SPRINT study, which had 
2% of patients8 with at least one BG < 2.2 mmol/liter, 2.8% 
of BG < 4.0, and 0.2% of BG < 3.0 mmol/liter, respectively.
1472
A Pilot Study of the SPRINT Glycemic Control Protocol in a Hungarian Medical Intensive Care Unit Benyo
www.journalofdst.orgJ Diabetes Sci Technol Vol 6, Issue 6, November 2012
Hyperglycemia rates were raised, with approximately 10% 
(absolute) increase in %BG within 8.0–10 mmol/liter). 
This difference, and the associated reduction in per-
formance, can be attributed to the significant increase 
in initial BG, in conjunction with higher nutrition rates 
and use of insulin infusions (see Table 2). Thus Figure 6 
shows the first 48 h of control for these 12 patients, 
where each hour is a box and whisker plot showing the 
overall trend of control, reflecting the starting value and 
other factors.
With respect to clinical effort, there were 742 measure-
ments over 1088 h, yielding 16.4 measurements per day. 
Thus ~50% of the time is on measurements every 2 h per 
Figure 3. This value is very similar to the 16.2 averaged 
in the original SPRINT study.9
Figure 7 shows patient 6, whose response mimics that 
of the original SPRINT study best, with median (IQR) 
BG of 5.8 (5.3–7.0) mmol/liter and 73.1% of BG in the 
4.4–7.0 mmol/liter band, despite a higher carbohydrate 
Figure 6. Blood glucose results for all patients over the first 48 h of stay, showing initial BG and rate of control to a controlled steady state level.
nutrition of (median) 5.6 g/h. Figure 8 shows patient 
9 who had a very high 45% of their 75 h trial with BG 
between 8.0 and 10.0 mmol/liter. In this case, the plot 
clearly shows that SPRINT reduced nutrition as much 
as allowed and raised insulin to its maximum, while the 
BG was stubbornly around ~8.0–8.5 mmol/liter until 
the very end of the trial when normal BG levels were 
restored. Patient 9 is the source of much of the upward 
spread shown in Figure 6. Hence, this set of results 
shows how SPRINT was able to manage a highly 
resistant patient. Patient 3 also has over 35% time in the 
8.0–10.0 mmol/liter band, which, in this case, is due to a 
fixed and very high nutrition level that was specifically 
prescribed by the clinical staff. Thus this patient had 
insulin as the only means of managing BG levels and 
did so relatively well given the very high carbohydrate 
nutrition. Finally, Figure 9 shows patient 2, who had the 
approximately average BG response but for relatively higher 
nutrition rates, showing the ability of SPRINT to adapt and 
provide good control for a wide range of inputs. Overall, 
these patients represent a cross section of performance.
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Figure 7. Results for patient 6. The top plot shows the BG measurements, and the lower plot shows the insulin and nutrition administration.
Figure 8. Results for patient 9. The top plot shows the BG measurements, and the lower plot shows the insulin and nutrition administration.
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Discussion
SPRINT successfully maintained effective and safe 
glycemic control over all patients in this pilot study at an 
independent ICU. Performance was similar to that found 
in the original SPRINT study, which achieved statistically 
significant reductions in mortality for patients staying 
3 days or longer9 and in the rate and severity of organ 
failure.11 The tightness of control exceeds what is reported 
in other studies as measured by time in band, as well as 
median (IQR).20,34
In particular, there is minimal variability across patients, 
as seen in Figure 5 and Table 3. Thus, SPRINT was 
equally effective in managing both interpatient and 
intrapatient variability. Interpatient and intrapatient 
variability is characteristic of the highly dynamic critical 
care patient and a main cause of the difficulty for many 
protocols in achieving safe and accurate control.34 Failure to 
manage variability has resulted in significant crossover 
of patients between target bands in other studies, as well 
as poor control and reduced outcomes.34
Figure 9. Results for patient 2. The top plot shows the BG measurements, and the lower plot shows the insulin and nutrition administration.
The nutrition in this study was a mix of EN and PN, based 
on a local protocol, with ~50% carbohydrate content 
compared with the 35–40% used in the original SPRINT 
studies.9 This higher nutrition content is reflected in 
slightly higher insulin usage, as well as by the slightly 
higher median BG levels, when compared with the original 
SPRINT results in Tables 2 and 3. In addition, validated 
virtual trials35 suggest that using insulin infusions, rather 
than bolus delivery, could result in a similar, small overall 
increase in BG levels due to saturable insulin clearance 
mechanisms. Thus the BG distribution in this study is 
~0.5 mmol/liter higher for this unit than for the original 
SPRINT study, which is also reflected in the safety from 
BG < 4.0 mmol/liter in Table 2, as well as the control 
to steady state over hours 1–48 in Figure 6. This result 
is further reinforced when comparing the pilot results 
to those in Christchurch in Table 2 for the 4.0–7.75 and 
4.4–8.0 mmol/liter results. The Gyula pilot results for 
4.4–8.0 mmol/liter (80.9%) are much closer to those of SPRINT 
in Christchurch for the lower 4.0–7.0 mmol/liter range 
(82.8%). Hence, the results reflect ~0.5 to 0.8 mmol/liter 
shift to higher BG values because of these changes, given 
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that measurement and intervention rates were similar. 
However, it is important to note that the overall control 
is still comparable to SPRINT, more clearly showing 
robustness in the protocol’s ability to manage clinical 
practice differences.
A major limitation to this study, and any similar study, is 
that no such protocol may be rigidly used in exactly the 
same fashion at a different unit. Differences in clinical 
practice and culture, as well as staffing levels and a wide 
range of other factors, make this extremely difficult to 
do without a formal rigid clinical trial. However, such a 
trial was not a goal of this study, which was to assess 
if the SPRINT protocol would generalize across those 
boundaries, safely and effectively.
Thus it is important to note that, despite the differences 
in clinical practice and culture noted earlier (insulin 
infusions, PN + EN delivery of higher carbohydrate) that 
SPRINT was able to provide effective and safe control 
in this pilot trial whose primary goal was to determine 
whether those outcomes would occur. It is important 
to note that the changes noted were all based around 
clinical practice culture, rather than specific changes to 
dosing recommendations or the way in which SPRINT 
was used by nursing staff. This type of change better reflects 
the conditions under which any reported protocol might 
be picked up and used by an interested ICU, rather than 
a strict clinical trial comparison, as it tests the impact of 
those clinical practice and cultural differences that occur 
naturally between hospitals and countries.
Overall, there are two important conclusions to draw from 
this pilot study. First is that SPRINT is readily transferrable 
to other clinical practice cultures and approaches, as well 
as to another language. It is important to note that the 
protocol was flexible enough to allow insulin infusion 
delivery, rather than the bolus delivery of the first study,9 
and that it did not significantly or unexpectedly affect 
the results or control. Second, SPRINT was equally 
effective and safe in this different ICU, indicating the 
robustness of this control method that modulates both 
insulin and nutrition to achieve control, which is unique 
to SPRINT, to differences in clinical practice and culture.
Thus it should be noted that, while discussed in detail 
in the original study, this approach of modulating 
nutrition in addition to exogenous insulin is a significant 
departure from other approaches that use insulin 
alone.6,7,28,36–41 Despite concerns, studies show that low-
calorie nutritional inputs reduce hyperglycemia42–46 and, 
above ~30% of standard goal feed rate, do not increase 
infectious complications.47–49 More specifically, Krishnan 
and coauthors50 showed that feeding over 66% of the ACCP 
recommended rates increased the likelihood of ICU 
mortality and suggested that the ACCP caloric targets 
may be too high. In addition, hyperglycemia has also 
been shown to exacerbate muscle protein catabolism 
in burn patients,51 indicating that excessive nutrition 
and hyperglycemia should be avoided as well. Finally, 
reduced caloric nutritional support has been effective 
in pediatric cases and for the obese.45,48,52 Thus there is 
reasonable evidence to support the use of moderate, not 
eliminated, reductions in nutrition.
A further limitation of this study is the 12 patient total, 
which is not large. However, the main goal was to 
test the robustness of the protocol to being transferred 
safely and effectively across clinical practice culture and 
approach to insulin and nutrition administration, which 
can vary quite widely, as well as the need to be robust 
to other human factors.30 This safety and efficacy goal 
has been shown at least for this initial study. Equally, 
the 1088 h of control is a relatively larger number and 
indicates that the results are not likely due to novelty or the 
caution of using a new protocol. Thus, while ongoing use 
will show whether the results holds true over time, these 
results indicate that further use does not appear to carry 
risk or require specialized modification for this unit.
Finally, SPRINT was fully implemented by nursing 
staff without additional clinical intervention using the 
SPRINT protocol in Figures 1 and 2 in translated format. 
Frequent BG measurement required by SPRINT was 
accepted by nurses, as the protocol prescribes definitive 
actions, as the measurement rates were similar to those 
in SPRINT. There was no reported concern regarding 
workload or ease of use.
Conclusions
This is a pilot study of a 12-patient cohort with 1088 h of 
BG control using the SPRINT protocol in an independent 
ICU. Blood glucose was safely and tightly controlled. 
Interpatient variability of control was also low. There were 
no instances of severe hypoglycemia. Results are 
similar to those of the pilot and full SPRINT studies 
from Christchurch, where it was designed and first 
implemented, which indicates the robustness of this 
specific protocol to different clinical practice cultures 
and approaches despite the differences in insulin and 
nutrition administration required to fit into this specific 
unit’s clinical practice.
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